期刊
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
卷 10, 期 3, 页码 224-231出版社
SPRINGER
DOI: 10.1007/s11910-010-0105-7
关键词
Low-grade glioma; Astrocytoma; Oligodendroglioma; Oligoastrocytoma; Mixed glioma; IDH; Molecular cytogenetics; Chemotherapy; Temozolomide; Radiation therapy
The optimal management of patients with low-grade glioma (LGG) is controversial. The controversy largely stems from the lack of well-designed clinical trials with adequate follow-up to account for the relatively long progression-free survival and overall survival of patients with LGG. Nonetheless, the literature increasingly suggests that expectant management is no longer optimal. Rather, there is mounting evidence supporting active management including consideration of surgical resection, radiotherapy, chemotherapy, molecular and histopathologic characterization, and use of modern imaging techniques for monitoring and prognostication. In particular, there is growing evidence favoring extensive surgical resection and increasing interest in the role of chemotherapy (especially temozolomide) in the management of these tumors. In this review, we critically analyze emerging trends in the literature with respect to management of LGG, with particular emphasis on reports published during the past year.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据